BioWin

Supporting innovation is critical to guaranteeing Wallonia's industrial future. Four industry leaders urge the new Walloon Government not to cut funding for innovation, the "key to Wallonia's reindustrialisation." Melanie Mestdagt (EyeD Pharma), jean JOUET (Rely), François Lepot (Safran), and Guy Paternoster (Raffinerie Tirlemontoise) are rallying to preserve this strategic lever, essential for reindustrialising and boosting the competitiveness of Walloon companies. Melanie Mestdagt: "A company like mine doesn’t always have the resources to gather all the information about innovation. The clusters provide us with a valuable knowledge network." Clusters impact in figures: ➡️ 78% added value generated by cluster members (2013–2022), compared to +6% for Wallonia's overall industry ➡️ 573 collaborative projects funded since 2007 ➡️ 27.5% job growth in cluster-related sectors since 2013, while employment in other industrial sectors has declined 👉 See the full article (FR): https://lnkd.in/ekSVTrXJ Pôle MecaTech, Wagralim, the Agri-Food Innovation Cluster of Wallonia, Sylvie Ponchaut, EyeD Pharma, Rely, Safran, Raffinerie Tirlemontoise - Tiense Suikerraffinaderij, Francois Xavier Lefevre

An important milestone for LiveDrop Bio: the company has launched the commercialisation of its high-tech instrument for sorting biological cells. ModaFlow 4L5C, which is based on droplet microfluidic technology, empowers laboratories to bring new treatments to market faster and more cost-effectively. "Droplet microfluidics integrated with LiveDrop’s advanced bioassays is revolutionising immunology research. These tools enable high-throughput B-cell screening, monoclonal antibody discovery, and single-cell antibody response studies with unmatched precision. A game-changer technology to support innovation in Life Sciences. By rapidly screening plasma cells and Fc receptor interactions, LiveDrop drive breakthroughs in autoimmune and allergy therapies, transforming our understanding of human immunity." — Dr. Adrien Boes, CER Groupe, Belgium 👉 See the full release: https://lnkd.in/ehBsVYtm

Member news! UCB partners with Ailux Biologics, a division of XtalPi, on biologics AI platform. Under the agreement, Ailux Biologics grants UCB a non-exclusive license to leverage XtalFold™ for the discovery and engineering of biologics. XtalFold™ is a proprietary AI-based software suite that provides rapid and accurate structural insights to accelerate biologics innovation across multiple phases. Computational advancements enable earlier and more widespread use of antibody-antigen structural insights across drug discovery process. “Our decision to license this tool comes after extensive testing and evaluation against other computational approaches and we believe it has the potential to enhance UCB’s ability to rapidly and efficiently discover high quality therapeutic antibody candidates and ultimately deliver new medicines to patients,” said Alexander Hillisch, Head of Global CADD, UCB. 👉 See the full release: https://lnkd.in/em74jnnG

neuroClues has received MDR certification to market its early detection device for neurodegenerative diseases in Europe. To have a medical device certified in Europe before the United States is highly uncommon. It challenges the perception that the European Union’s fragmented market and complex regulations discourage innovation. Yet, this is exactly what neuroClues has just achieved. "Innovation is still possible in Europe," says CEO Antoine Pouppez. 👉 Read the full release: https://lnkd.in/ewhYp7yi 👉 Read the article: https://lnkd.in/efTtDM2A

From all of us at BioWin, we wish you a joyful holiday season filled with warmth, laughter, and sweet moments. 🎅 see you all in 2025! 

The Full-Life Technologies project is taking good shape in Gembloux, Belgium. This radioisotope manufacturing facility represents an €80 million investment and will ultimately create around 50 jobs. By 2026, under full capacity, it will provide Ac-225 therapies to tens of thousands of cancer patients each year 🤯 The construction of the facility started in December 2023 and obtained a Nuclear Permit for a class IIA facility from the Belgium Federal Agency for Nuclear Control in March 2024. Check out with Philippe van Put the amazing progress they have made so far!

It feels like the Christmas season has arrived a little early at Telix Manufacturing Solutions in Brussels South, where two new cyclotrons have been installed. These cyclotrons, supplied by GE HealthCare and IBA, strengthens Telix's position as a major nuclear medicine production facility, serving as the Company’s primary manufacturing site for radioisotopes and patient doses across the EMEA region and beyond. Darren Patti, Group Chief Operating Officer, Telix Pharmaceuticals Limited said, “This year, more than 10 million radiopharmaceutical procedures will be performed in the EU. These new cyclotrons, manufactured by the world leaders in particle accelerator technology, will deliver significant flexibility and reliable supply from Telix’s first bench-to-bedside manufacturing facility, to help meet this growing demand." 👉 Read the full release: https://lnkd.in/e9Wb-2mh

Member news! Bioxodes meets enrollment milestone in Phase 2a intracerebral hemorrhagic stroke trial. "We’ve reached a crucial point in the development of BIOX-101, which we believe can save lives, and improve quality of life," said Marc Dechamps, Chief Executive Officer at Bioxodes. 👉 Read the full release: https://lnkd.in/eVCg2GQs

✨ An early christmas gift for IRE - Institute for radioelements with the arrival of a 30 MeV IBA cyclotron at its Fleurus site. Total investment: over 30 million euros, including five million for the cyclotron alone. This “strategic investment” marks a “decisive step in IRE's drive to expand its production capacity and strengthen its leadership in radiopharmaceutical production. Erich Kollegger, CEO of IRE, stated: "The arrival of the IBA cyclotron is a significant turning point in IRE's history. This project demonstrates our capacity to innovate, diversify our activities, and control the entire production chain of essential radionuclides for nuclear medicine. We are committed to meeting the growing market needs and maintaining our position as an industry leader." 👉 See full article (French): https://lnkd.in/e5nt9K_r 👉 See full release: https://lnkd.in/e-Ka5sUr

Looking for funding to support your research on #RareDiseases? A new European funding opportunity has been launched to support collaborative research on rare diseases under the Horizon Europe program. This initiative is co-funded by the Service public de Wallonie as part of the ERDERA partnership. 👉 Learn more about the call: https://lnkd.in/dTQgBNuy